Pregnancy in Upshaw-Schulman syndrome

K. Kentouche; A. Voigt; E. Schleussner; R. Schneppenheim; U. Budde; J. F. Beck; E. Stefanska-Windyga; J. Windyga

doi:10.5482/HAMO-13-04-0025

Hämostaseologie, Table of Contents

Hamostaseologie 2013; 33(02): 144-148
DOI: 10.5482/HAMO-13-04-0025

Case report

Schattauer GmbH

Pregnancy in Upshaw-Schulman syndrome

Schwangerschaft bei Upshaw-Schulman-Syndrom

K. Kentouche

¹Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Jena, Germany

,

A. Voigt

¹Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Jena, Germany

,

E. Schleussner

²Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Jena, Germany

,

R. Schneppenheim

³Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Germany

,

U. Budde

⁴MEDILYS Laborgesellschaft mbH, Hamburg, Germany

,

J. F. Beck

¹Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Jena, Germany

,

E. Stefanska-Windyga

⁵Institute of Haematology and Transfusion Medicine, Warsaw, Poland

,

J. Windyga

⁵Institute of Haematology and Transfusion Medicine, Warsaw, Poland

› Author Affiliations

Abstract

Summary

The Upshaw Schulman syndrome (MIM #274150) is a hereditary deficiency of the von Willebrand factor cleaving protease (ADAMTS13) due to homozygous or compound heterozygous mutations in the ADAMTS13 gene. Patients are prone to bouts of thrombotic thrombocytopenic purpura. However, disease manifestation needs a second trigger event. Pregnancy is a known risk factor for TTP. Patients with USS may manifest during pregnancy and the postpartum period or relapse with a TTP bout. Before plasma therapy mortality for both the mother and the fetus was high, but even nowadays when plasma is delivered, therapy is challenging, still bearing a high risk for miscarriage or long term sequelae for the mother.

In this report on pregnancies in three mothers with USS, plasma therapy was increased in frequency and amount given with regard to platelet count or ADAMTS13 activity, thus leading to a successful outcome.

Zusammenfassung

Beim Upshaw Schulman Syndrom (#274150) besteht ein angeborener Mangel der von-Willebrand-Faktor-spaltenden Protease (ADAMTS13) durch homozygote oder kombiniert heterozygote Mutationen im ADAMTS13-Gen. Dadurch kommt es bei den Patienten zu Schüben mit dem Bild der thrombotisch-thrombozytopenischen Purpura . Allerdings braucht es für diese Manifestation einen Auslöser. Schwangerschaft stellt einen bekannten Risikofaktor für die TTP dar. Bei Patientinnen mit USS kommt es entweder zur Erstmanifestation während der Schwangerschaft oder im Wochenbett oder zum Rückfall der TTP. Vor der Einführung der Plasmatherapie lag die Mortalität für Mutter und Kind hoch, doch auch heute mit Plasmasubstitution, stellt die Behandlung eine Herausforderung dar, mit einem hohen Risiko für vorzeitigen Abort oder Langzeitschäden bei der Mutter.

In diesem Bericht über Schwangerschaften dreier Mütter mit USS, führte die an die Blutplättchenzahl oder ADAMTS13-Aktivität angepasste Plasmagabe zu erfolgreichem Schwangerschaftsverlauf.

Keywords

Upshaw Schulman syndrome - pregnancy - TTP - plasma therapy - VWF - ADAMTS13

Schlüsselwörter

Upshaw-Schulman-Syndrom - Schwangerschaft - TTP - Plasmatherapie - ADAMTS13

Full Text

References

References
1 Abou-Nassar K, Karsh J, Giulivi A, Allan D. Successful prevention of thrombotic thrombocytopenic purpura (TTP) relapse using monthly prophylactic plasma exchanges throughout pregnancy in a patient with systemic lupus erythematosus and a prior history of refractory TTP and recurrent fetal loss. Transfus Apher Sci 2010; 43: 29-31.
2 Calderazzo JC, Kempfer AC, Powazniak Y. et al. A new ADAMTS13 missense mutation (D1362V) in thrombotic thrombocytopenic purpura diagnosed during pregnancy. Thromb Haemost 2012; 108: 401-403.
3 Camilleri RS, Cohen H, Mackie IJ. et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 06: 331-338.
4 Cosmai EM, Puzis L, Tsai HM, Lian ECY. Thrombocytopenic purpura and cardiomyopathy in pregnancy reversed by combined plasma exchange and infusion. Eur J Haematol 2002; 68: 239-242.
5 D’Angelo A, Fattorini A, Crippa L. Thrombotic microangiopathy in pregnancy. Thromb Res 2009; 123 (Suppl. 02) 56-62.
6 Ducloy-Bouthors AS, Caron C, Subtil D. et al. Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. Eur J Obstet Gynecol Reprod Biol 2003; 111: 146-152.
7 Fujimura Y, Matsumoto M, Kokame K. et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw–Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2008; 144: 742-754.
8 Ganesan C, Maynard SE. Acute kidney injury in pregnancy: the thrombotic microangiopathies. J Nephrol 2011; 24: 554-563.
9 Gerth J, Schleussner E, Kentouche K. et al. Pregnancy-associated thrombotic thrombocytopenic purpura. Thromb Haemost 2009; 101: 248-251.
10 Hunt BJ, Thomas-Dewing RR, Bramham K, Lucas SB. Preventing maternal deaths due to acquired thrombotic thrombocytopenic purpura. J Obstet Gynaecol Res 2013; 39: 347-350.
11 Ilter E, Haliloglu B, Temelli F, Ozden S. Thrombotic thrombocytopenic purpura and pregnancy treated with fresh-frozen plasma infusions after plasmapheresis: a case report. Blood Coagul Fibrinolysis 2007; 18: 689-690.
12 Kato R, Shinohara A, Sato J. ADAMTS13 deficiency, an important cause of thrombocytopenia during pregnancy. Int J Obstet Anesth 2009; 18: 73-77.
13 Kemp W, Barnard JJ, Prahlow JA. Death due to thrombotic thrombocytopenic purpura in pregnancy: Case report with review of thrombotic microangiopathies of pregnancy. Am J Forensic Med Pathol 1999; 20: 189-198.
14 Kentouche K, Budde U, Furlan M. et al. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 2002; 91: 1056-1059.
15 Kremer JAHovinga, Vesely SK, Terrell DR. et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura Blood. 2010; 115: 1500-1511.
16 Lattuada A, Rossi E, Calzarossa C. et al. Mild to moderate reduction of a von Willebrand cleaving protease (ADAMTS13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-1034.
17 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves vonWillebrand factor. Blood 2001; 98: 2730-2735.
18 Martin Jr JN, Bailey AP, Rehberg JF. et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955–2006. Am J Obstet Gynecol 2008; 199: 98-104.
19 Matsumoto M, Yagi H, Ishizashi H. et al. The Japanese experience with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
20 McCrae KR. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program 2010; 397-402.
21 Moatti-Cohen M, Garrec C, Wolf M. et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-5897.
22 Raman R, Yang S, Wu HM, Cataland SR. ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. Br J Haematol 2011; 153: 277-279.
23 Rizzo C, Rizzo S, Scirè E. et al. Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange. Blood Transfus 2012; 10: 521-532.
24 Scully M, Hunt BJ, Benjamin S. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335.
25 Scully M, Starke R, Lee R. et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 459-463.
26 Scully M, Yarranton H, Liesner R. et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features Br J Haematol. 2008; 142: 819-826.
27 Sharma A, Radotra B, Wanchu A. et al. Thrombotic thrombocytopenic purpura in a patient with very early pregnancy: clinical presentation and autopsy findings. Blood Coagul Fibrinolysis 2008; 19: 727-730.
28 Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol 2009; 33: 196-205.
29 Sié P, Caron C, Azam J. et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121: 897-903.
30 Stella CL, Dacus J, Guzman E. et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200: 381-386.
31 Taché V, Towner D, Xing G, Gilbert W. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in pregnancy: A population based study. Am J Obstet Gynecol 2006; 195: 202.
32 Veyradier A, Stepanian A, Coppo P. ADAMTS13, thrombotic thrombocytopenic purpura and pregnancy. Hereditary Genetics 2012; S1: 002.
33 Yamamoto T, Fujimura Y, Emoto Y. et al. Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura. J. Obstet Gynaecol Res 2013; 39: 351-354.